Breakthrough

• Researchers at CERN's Large Hadron Collider detected rare Higgs boson decay patterns that deviate from Standard Model predictions, suggesting potential physics beyond current theoretical frameworks. • The analysis examined 150 billion particle collisions collected over two years, revealing a 3.2 sigma deviation in the boson's decay pathways, announced on April 20 by the ATLAS and CMS collaborations. • The findings could indicate undiscovered particles or fundamental forces and represent significant progress toward understanding the universe's most elusive particles.

• NASA's Perseverance rover discovered extensive water ice deposits beneath Mars' surface in Jezero Crater using advanced ground-penetrating radar technology, with findings suggesting accessibility for future human missions. • The subsurface ice layers extend up to 300 meters deep and contain an estimated 5 million metric tons of water ice, according to data released by NASA's Jet Propulsion Laboratory on April 21. • Scientists believe the water deposits could support long-term human habitation and fuel production, making Mars exploration more feasible for sustained presence beyond current rover missions.

• Google unveiled a new quantum processor featuring 10,000 qubits on April 19, claiming achievement of quantum advantage for practical optimization problems with error rates reduced by 60% compared to previous generations. • The chip, named Willow, successfully solved complex combinatorial optimization problems approximately one million times faster than classical supercomputers according to Google Quantum AI division testing. • The breakthrough potentially accelerates commercialization of quantum computing for applications including drug discovery, financial modeling, and supply chain optimization, attracting increased competition from IBM and IonQ.

• McGovern Medical School at UTHealth Houston launched the Center for Innovation in Congenital Heart Disease, a multidisciplinary center bringing together experts in medicine, science, and engineering to transform understanding and treatment of the condition. • A major research focus involves recreating early human heart development using stem cells and bioprinted structures to study how congenital defects form. • The center bridges discovery and clinical care by advancing research, developing technologies, and translating innovations into patient treatment solutions across a lifetime of care.

• Scientists at the Indian Institute of Science, working with collaborators from Japan's National Institute for Materials Science, have observed electrons in graphene flowing like a nearly frictionless liquid, defying a core law of physics. • Researchers created exceptionally clean graphene samples and measured electrical and thermal conductivity, finding that as electrical conductivity rose, thermal conductivity dropped—the opposite of expected behavior. • The team discovered the fluid's viscosity is extremely low, making it one of the closest realizations of a perfect fluid ever observed, establishing graphene as an accessible platform for studying extreme physics phenomena.

• Researchers from Binghamton University and University of Virginia developed a machine-learning system that analyzed over 55 million scientific papers and patents to identify truly disruptive research that changes the direction of science. • The new metric, published in Science Advances, measures "disruptiveness" — the degree to which a paper pulls a field away from its earlier path — and successfully identifies major simultaneous discoveries often overlooked by traditional citation-based measures. • The study addresses a critical gap in how science evaluates impact, recognizing that scientific progress occurs through abrupt changes rather than incremental steps, helping identify overlooked breakthrough moments in research history.

• The MajesTEC-3 clinical trial led by UAB researchers demonstrates that a new two-drug immunotherapy regimen can lead to long-lasting remission for multiple myeloma patients. • Over 83 percent of patients enrolled in the trial remain alive and progression-free three years after therapy, supporting approval of this potentially curative treatment. • The findings represent a significant advance for multiple myeloma, a blood cancer with limited treatment options historically.